Lipidomics Consulting provides unique help at any phase in your lipidomics workflow. We help you to establish, customize and support the technologie(s) of your interest, aiming to maximize your productivity.
Lipidomics Consulting Ltd was founded in May 2016 by Dr. Kim Ekroos, who is the CEO of the company. Kim received his Ph.D. degree in biology from the Technical University in Dresden, Germany, in 2003. His expertise includes high-throughput technologies for the precise assessment of lipidomes enabled by advanced mass spectrometry, automation, and software tools towards discovery of biological architectures and of diagnostic biomarkers for clinical purpose. He is one of the pioneers in lipidomics, with more than 20 years of experience in the academic, industry and regulatory disciplines of lipidomics and lipid biology. His work is well recognized, applied world-wide, and has had a great impact on the development of the whole Lipidomics field. His work has among others resulted in the first-ever establishment of lipidomics based lipid biomarkers in clinical diagnostics. He has granted patents, more then 60 peer-reviewed publications, contributed with a Lipidomics book, and presented and chaired at multiple international conferences. Kim is a co-founder of the Lipidomics Standards Initiative (LSI) and the president of the International Lipidomics Society (ILS).
HELSINKI, March 10, 2023 – Lipidomics Consulting Ltd, a front-running lipidomics company that is fundamentally changing how understanding the mechanistic and metabolic details of lipids are investigated in disease, together with scientists at University of Wollongong (UoW) and Aspect Analytics NV have received a grant
Matrix-assisted laser desorption ionization–mass spectrometry imaging (MALDI-MSI) is an emerging label-free method for mapping the distribution of diverse molecular species in tissue sections. Despite recent progress in MALDI-MSI analyses of lipids, it is still difficult to visualize minor bioactive lipids including lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P).
Defects in sphingolipid metabolism have emerged as a common link across neurodegenerative disorders, and a deeper understanding of the lipid content in preclinical models and patient specimens offers opportunities for development of new therapeutic targets and biomarkers.